Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

American Journal of Kidney Diseases

Volumn 68, Issue 2, 2016, Pages 287-291

  Shirali, Anushree C ^a   Perazella, Mark A ^a   Gettinger, Scott ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute interstitial nephritis (AIN); acute kidney injury (AKI); advanced melanoma; anti PD 1 antibody; immune checkpoint inhibitor; ipilimumab; nephrotoxicity; nivolumab; non small cell lung cancer (NSCLC); PD 1; PD 1 inhibitor; PDCD1; pembrolizumab; Programmed cell death 1; renal biopsy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; FUROSEMIDE; IPILIMUMAB; LISINOPRIL; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NIVOLUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED CELL DEATH 1 INHIBITOR; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CANCER PATIENT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN TISSUE; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; LUNG CANCER; MALE; MIDDLE AGED; MYOPATHY; NAUSEA; NON SMALL CELL LUNG CANCER; RASH; SIDE EFFECT; T LYMPHOCYTE; URINE VOLUME; ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CASE REPORT; CELL DEATH; CHEMICALLY INDUCED; DRUG EFFECTS; LUNG NEOPLASMS;

ACUTE DISEASE; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEPHRITIS, INTERSTITIAL;

EID: 84963948616     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.02.057     Document Type: Article

References (18)

1. 1 Dong, H., Zhu, G., Tamada, K., Chen, L., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5:12 (1999), 1365–1369.
2. 2 Freeman, G.J., Long, A.J., Iwai, Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:7 (2000), 1027–1034.
3. 3 Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:26 (2012), 2443–2454.
4. 4 Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:2 (2013), 134–144.
5. 5 Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:21 (2015), 2018–2028.
6. 6 Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:2 (2015), 123–135.
7. 7 Geevasinga, N., Coleman, P.L., Webster, A.C., Roger, S.D., Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 4:5 (2006), 597–604.
8. 8 Nishino, M., Sholl, L.M., Hodi, F.S., Hatabu, H., Ramaiya, N.H., Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373:3 (2015), 288–290.
9. 9 Eremina, V., Cui, S., Gerber, H., et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 17:3 (2006), 724–735.
10. 10 Voskens, C.J., Goldinger, S.M., Loquai, C., et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PloS One, 8(1), 2013, e53745.
11. 11 Fadel, F., El Karoui, K., Knebelmann, B., Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361:2 (2009), 211–212.
12. 12 Izzedine, H., Gueutin, V., Gharbi, C., et al. Kidney injuries related to ipilimumab. Invest New Drugs 32:4 (2014), 769–773.
13. 13 Porta, C., Cosmai, L., Gallieni, M., Pedrazzoli, P., Malberti, F., Renal effects of targeted anticancer therapies. Nat Rev Nephrol 11:6 (2015), 354–370.
14. 14 Francisco, L.M., Sage, P.T., Sharpe, A.H., The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236 (2010), 219–242.
15. 15 Waeckerle-Men, Y., Starke, A., Wuthrich, R.P., PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. Nephrol Dial Transplant 22:6 (2007), 1527–1536.
16. 16 Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T., Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:2 (1999), 141–151.
17. 17 Hughes, J., Vudattu, N., Sznol, M., et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38:4 (2015), e55–e57.
18. 18 Spanou, Z., Keller, M., Britschgi, M., et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 17:10 (2006), 2919–2927.